Marquez Béatrice, Caceres Nancy E, Mingeot-Leclercq Marie-Paule, Tulkens Paul M, Van Bambeke Françoise
Unité de Pharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, UCL 7370 Avenue Mounier 73, B-1200 Brussels, Belgium.
Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6. doi: 10.1128/AAC.01428-08. Epub 2009 Mar 23.
Ciprofloxacin, the most widely used totally synthetic antibiotic, is subject to active efflux mediated by a MRP-like transporter in wild-type murine J774 macrophages. To identify the transporter among the seven potential Mrps, we used cells made resistant to ciprofloxacin obtained by long-term exposure to increasing drug concentrations (these cells show less ciprofloxacin accumulation and provide a protected niche for ciprofloxacin-sensitive intracellular Listeria monocytogenes). In the present paper, we first show that ciprofloxacin-resistant cells display a faster efflux of ciprofloxacin which is inhibited by gemfibrozil (an unspecific MRP inhibitor). Elacridar, at a concentration known to inhibit P-glycoprotein and breast cancer resistance protein (BCRP), only slightly increased ciprofloxacin accumulation, with no difference between resistant and wild-type cells. Analysis at the mRNA (real-time PCR) and protein (Western blotting) levels revealed an overexpression of Mrp2 and Mrp4. Mrp4 transcripts, however, were overwhelmingly predominant (45% [wild-type cells] to 95% [ciprofloxacin-resistant cells] of all Mrp transcripts tested [Mrp1 to Mrp7]). Silencing of Mrp2 and Mrp4 with specific small interfering RNAs showed that only Mrp4 is involved in ciprofloxacin transport in both ciprofloxacin-resistant and wild-type cells. The study therefore identifies Mrp4 as the most likely transporter of ciprofloxacin in murine macrophages but leaves open a possible common upregulation mechanism for both Mrp4 and Mrp2 upon chronic exposure of eukaryotic cells to this widely used antibiotic.
环丙沙星是使用最广泛的全合成抗生素,在野生型小鼠J774巨噬细胞中,它会受到一种类多药耐药相关蛋白(MRP)转运体介导的主动外排作用。为了在7种潜在的多药耐药相关蛋白中鉴定出该转运体,我们使用了通过长期暴露于不断增加的药物浓度而获得的对环丙沙星耐药的细胞(这些细胞中环丙沙星的蓄积较少,为对环丙沙星敏感的细胞内单核细胞增生李斯特菌提供了一个受保护的生态位)。在本文中,我们首先表明,对环丙沙星耐药的细胞中环丙沙星的外排更快,而吉非贝齐(一种非特异性MRP抑制剂)可抑制这种外排。艾拉莫德在已知可抑制P-糖蛋白和乳腺癌耐药蛋白(BCRP)的浓度下,仅略微增加了环丙沙星的蓄积,耐药细胞和野生型细胞之间没有差异。在mRNA(实时PCR)和蛋白质(蛋白质印迹法)水平上的分析显示,多药耐药相关蛋白2(Mrp2)和多药耐药相关蛋白4(Mrp4)过表达。然而,Mrp4转录本在所有检测的Mrp转录本(Mrp1至Mrp7)中占绝大多数(野生型细胞中占45%,环丙沙星耐药细胞中占95%)。用特异性小干扰RNA沉默Mrp2和Mrp4表明,在环丙沙星耐药细胞和野生型细胞中,只有Mrp4参与环丙沙星的转运。因此,该研究确定Mrp4是小鼠巨噬细胞中环丙沙星最可能的转运体,但对于真核细胞长期暴露于这种广泛使用的抗生素后Mrp4和Mrp2共同上调的可能机制仍未明确。